Table 1 Demographic and clinical information of patients stratified by treatment type

Age, median(IQR), y

69(58–79)

65(55–79)

71(61–80)

65(54–74)

0.444

Male, %

55

48

58

75

0.600

Active smoking, %

29

14

38

25

0.193

Comorbidities, %

Hypertension, %

69

86

59

75

0.095

Diabetes mellitus, %

34

33

38

0

0.269

Atrial fibrillation, %

66

67

65

75

1.000

Coronary artery disease, %

35

48

32

0

0.097

Congestive heart failure, %

13

10

14

25

0.567

Chronic renal insufficiency, %

13

14

11

25

0.459

ASA > 3

27

5

41

25

0.009

Duration of symptoms onset to treatment,

median (IQR), h

48(18–120)

24(11–120)

48(24–120)

132(30–168)

0.214

Abdominal pain, %

98

100

97

100

1.000

Emesis, %

61

67

62

25

0.376

Diarrhea, %

35

33

35

50

0.833

Hematochezia, %

23

10

32

0

0.094

WBC count, mean ± SD, × 10³/dL

15 ± 9

13 ± 7

17 ± 10

14 ± 8

0.278

Neutrophil ratio median (IQR), %

87(81–90)

87(74–89)

87(82–91)

87(68–92)

0.676

Urea, mean ± SD, mmol/L

9 ± 5

8 ± 6

9 ± 4

11 ± 9

0.679

Creatinine, mean ± SD, umol/L

107 ± 117

126 ± 182

92 ± 35

121 ± 74

0.592

Potassium, mean ± SD, mg/dL

4.0 ± 0.6

3.8 ± 0.6

4.1 ± 0.5

4.2 ± 0.8

0.231

Alanine transaminase, median (IQR), U/L

17(13–30)

15(11.3–28.0)

21.0(12.8–37.3)

20.5(14.0-2649.8)

0.449

Aspartate transaminase, median (IQR), U/L

25(17–48)

22.4(14.4–37.2)

32.4(18.7–54.5)

20.0(16.4-7284.3)

0.294

Lactate, median (IQR), mmol/L

3.3 ± 2.2

2.5 ± 2.5

3.6 ± 2.2

1.5 ± 0.5

0.175

D-dimer (IQR), mg/L

2.3(1.1–4.5)

2.3(1.7–8.5)

2.3(1.1-4.0)

0.9(0.3-8.0)

0.360

Occlusion segmentation of SMA

S1, %

21

24

16

50

0.224

S2, %

30

42

27

25

0.748

S3, %

13

19

11

0

0.684

S1-S2, %

10

0

16

0

0.138

S2-S3, %

21

15

27

25

0.259

S1-S3, %

2

5

0

0

0.403

S1-S2-S3, %

3

5

3

0

1.000